IP Library Granted Patent US 12,582,749
Granted Patent B2
US 12,582,749 · App. 17/568,148 · Granted Mar 24, 2026

Meniscus tear repair sling device

Inventors: Timothy Ganey (Tampa, FL); Paul Saluan (Westlake, OH)
Assignee: Vivex Biologics Group, Inc.
A61L27/3654A61F2/30756A61F2/4618A61L27/3604A61L27/54A61F2002/30757A61L2300/414A61L2430/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,749
App. No.
17/568,148
Granted
Mar 24, 2026
Kind
B2
Abstract

A meniscus tear repair sling device has a collagen membrane having a first end portion and a second end portion. The first end portion is configured to pass under a tear in a meniscus and wrap over and above the tear and extend past the meniscus and overlay the second end portion thereby enveloping a portion of the meniscus with a tear and forming the sling device. The first end portion and the second end portion form exposed overlying tails extending external of a knee joint. The tails are configured to be affixed to a portion of a tibia. The tails when tensioned close the tear by providing a lateral strain on the torn meniscus when the tails are affixed to a tibia adjacent the knee joint.

Claims (14)

1 . A method of performing a meniscus tear repair, comprising:

providing a collagen membrane having a first end portion and a second end portion, wherein the collagen membrane comprises one or more of an amniotic membrane, a placental tissue membrane, and an umbilical cord membrane; wherein the first end portion is configured to pass under a tear in a meniscus and wrap over and above the tear and extend past the meniscus and overlay the second end portion, thereby forming a sling device wherein the first end portion and the second end portion form exposed overlying tails extending externally from a knee joint, the tails, when tensioned, close the tear by providing a lateral strain on the torn meniscus when affixed to a tibia adjacent the knee joint;

inserting the device inside a cannula, the device being rolled to form a cylindrical shape sized to fit inside the cannula;

inserting the cannula into the knee joint, delivering the device to wrap over and under the meniscal tear;

pulling the device at the first end portion to slide the device into position and leaving the first end portion and second end portion exposed external to the knee joint; and

tensioning the device to create a lateral strain and fixing the tails to the tibia, creating an intraarticular and interarticular extracapsular fixation, wherein the meniscus is not exposed to suture penetration.

2 . The method of claim 1 , wherein the collagen membrane comprises an inner surface and an outer surface, wherein the inner surface comprises biologic materials and growth factors to accelerate healing of the tear.

3 . The method of claim 2 , wherein the biologic materials and growth factors are selected from a group consisting of amino acids, purines, pyrimidines, vitamins, hyaluronic acid, acellular biologic material, amniotic fluid, and combinations thereof.

4 . The method of claim 2 , wherein the biologic materials comprise non-whole cellular components.

5 . The method of claim 2 , wherein the inner surface comprises exosomes.

6 . The method of claim 1 , wherein the collagen membrane comprises a polyampholyte protectant or cryoprotectant.

7 . The method of claim 6 , wherein the cryoprotectant comprises ε-poly-1-lysine.

8 . The method of claim 6 , wherein the collagen membrane is cryolyophilized, stored, and soaked in a liquid prior to use of the collagen membrane in the meniscus tear repair.

9 . The method of claim 1 , wherein the collagen membrane is cryolyophilized, stored, and soaked in a liquid prior to use of the collagen membrane in the meniscus tear repair.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2025
From: GANEY, TIMOTHY; SALUAN, PAUL
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 073003/0977 →
Continuity (2)
Provisional Application 63133606 · Jan 4, 2021
Related Publication 20220211909A1 · Jul 7, 2022
References Cited (38)
US 5061283A · Silvestrini · 1991 [cited by applicant]
US 5723008A · Gordon · 1998 [cited by applicant]
US 7871440B2 · Schwartz et al. · 2011 [cited by applicant]
US 7998204B2 · Stone · 2011 [cited by examiner]
US 8006700B2 · Demopulos et al. · 2011 [cited by applicant]
US 8084428B2 · Spector et al. · 2011 [cited by applicant]
US 8092529B2 · Malaviya · 2012 [cited by examiner]
US 8409250B2 · Schmieding et al. · 2013 [cited by applicant]
US 8814903B2 · Sengun et al. · 2014 [cited by applicant]
US RE45895E · Michelson · 2016 [cited by applicant]
US 9314234B2 · Hirotsuka · 2016 [cited by applicant]
US 9421304B2 · Shortkroff et al. · 2016 [cited by applicant]
US 9492592B2 · Hedman · 2016 [cited by applicant]
US 9675643B2 · Weston et al. · 2017 [cited by applicant]
US 9687511B2 · Weston et al. · 2017 [cited by applicant]
US 9724088B2 · Domingo · 2017 [cited by applicant]
US 9831354B2 · Li · 2017 [cited by applicant]
US 10251639B1 · Yamada · 2019 [cited by applicant]
US 10265438B1 · Brahm · 2019 [cited by examiner]
US 10299829B2 · Yamada · 2019 [cited by applicant]
US 10413572B2 · Namin et al. · 2019 [cited by applicant]
US 10433830B2 · Sengun et al. · 2019 [cited by applicant]
US RE47722E · Michelson · 2019 [cited by applicant]
US 10645921B2 · Temple et al. · 2020 [cited by applicant]
US 20040267277A1 · Zannis · 2004 [cited by examiner]
US 20070116682A1 · Atala et al. · 2007 [cited by applicant]
US 20070156174A1 · Kaiser · 2007 [cited by examiner]
US 20100228335A1 · Schorgl · 2010 [cited by applicant]
US 20110059178A1 · Semler · 2011 [cited by examiner]
US 20130030542A1 · Grotz · 2013 [cited by examiner]
US 20130344162A1 · Morse · 2013 [cited by applicant]
US 20150224147A1 · Tabet · 2015 [cited by examiner]
US 20160158291A1 · Kreke · 2016 [cited by applicant]
US 20170020927A1 · Ganey · 2017 [cited by examiner]
US 20170136071A1 · Danilkovitch et al. · 2017 [cited by applicant]
US 20230301786A1 · Thyden · 2023 [cited by examiner]
CN 102716515 · 2014 [cited by applicant]
WO 2015016761 · 2015 [cited by applicant]